Bellerophon Therapeutics Announces First Patient Treated in Phase 3 Clinical Study of INOpulse® Inhaled Nitric Oxide Therapy for COVID-19


You May Also Like

The Board of Directors of Orion Corporation decided on an incentive plan for key persons

                                                                         ORION CORPORATION  STOCK EXCHANGE RELEASE    2 FEB 2016  AT 14:45 PM EET               ...